Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.68 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.68 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26329799 | 1.00 | DDB1 (0.68) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL26329796 | 1.00 | DDB1 (0.68) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL29535454 | 1.00 | DDB1 (0.68) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL31639587 | 0.96 | DDB1 (0.64) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL23783207 | 0.95 | DDB1 (0.63) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL31333901 | 0.94 | DDB1 (0.61) | DDB1CRBN | |
| SCHEMBL31334450 | 0.93 | DDB1 (0.60) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL30207443 | 0.93 | DDB1 (0.60) | DDB1CRBN | |
| SCHEMBL27091551 | 0.93 | DDB1 (0.60) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL31451251 | 0.93 | DDB1 (0.68) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| EP-4385985-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117736187-B | Proteolysis targeting chimeric and preparation method, pharmaceutical composition and application thereof | 天津匠新致成科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117794936-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-03-29 | — | — | CN | disclosed |
| CN-117736187-A | Proteolysis targeting chimeric and preparation method, pharmaceutical composition and application thereof | 天津匠新致成科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-116891502-A | EGFR degrading agent | 上海齐鲁制药研究中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | DDB1 1230/4885CRBN 688/4885F13A1 2897/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | DDB1 397/4885CRBN 10/4885F13A1 3854/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | DDB1 390/4885CRBN 188/4885F13A1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.